O	0	4	Race
O	5	8	and
O	9	16	hormone
O	17	25	receptor
O	25	26	-
O	26	34	positive
O	35	41	breast
O	42	48	cancer
O	49	57	outcomes
O	58	60	in
O	61	62	a
O	63	73	randomized
B-intervention	74	86	chemotherapy
O	87	92	trial
O	92	93	.

O	94	97	The
O	98	109	association
O	110	117	between
O	118	123	black
O	124	128	race
O	129	132	and
O	133	138	worse
O	139	147	outcomes
O	148	150	in
O	151	159	operable
O	160	166	breast
O	167	173	cancer
O	174	182	reported
O	183	185	in
O	186	194	previous
O	195	202	studies
O	203	206	has
O	207	211	been
O	212	222	attributed
O	223	225	to
O	226	227	a
O	228	234	higher
O	235	244	incidence
O	245	247	of
O	248	252	more
O	253	263	aggressive
O	264	270	triple
O	270	271	-
O	271	279	negative
O	280	287	disease
O	287	288	,
O	289	300	disparities
O	301	303	in
O	304	308	care
O	308	309	,
O	310	313	and
O	314	327	comorbidities
O	327	328	.

O	329	331	We
O	332	341	evaluated
O	342	354	associations
O	355	362	between
B-ethinicity	363	368	black
I-ethinicity	369	373	race
O	374	377	and
O	378	386	outcomes
O	386	387	,
O	388	390	by
O	391	396	tumor
O	397	404	hormone
O	405	413	receptor
O	414	417	and
O	418	422	HER2
O	423	433	expression
O	433	434	,
O	435	437	in
B-eligibility	438	446	patients
I-eligibility	447	450	who
I-eligibility	451	455	were
I-eligibility	456	463	treated
I-eligibility	464	468	with
I-eligibility	469	481	contemporary
I-eligibility	482	490	adjuvant
I-eligibility	491	498	therapy
O	498	499	.

O	500	503	The
O	504	510	effect
O	511	513	of
O	514	519	black
O	520	524	race
O	525	527	on
O	528	535	disease
O	535	536	-
O	536	540	free
O	541	544	and
O	545	552	overall
O	553	561	survival
O	562	565	was
O	566	575	evaluated
O	576	581	using
O	582	585	Cox
O	586	598	proportional
O	599	606	hazards
O	607	613	models
O	614	622	adjusted
O	623	626	for
O	627	635	multiple
O	636	646	covariates
O	647	649	in
O	650	651	a
O	652	660	clinical
O	661	666	trial
O	667	677	population
O	678	682	that
O	683	686	was
O	687	694	treated
O	695	699	with
O	700	713	anthracycline
O	713	714	-
O	715	718	and
O	719	725	taxane
O	725	726	-
O	726	736	containing
O	737	749	chemotherapy
O	749	750	.

O	751	762	Categorical
O	763	772	variables
O	773	777	were
O	778	786	compared
O	787	792	using
O	793	796	the
O	797	803	Fisher
O	804	809	exact
O	810	814	test
O	814	815	.

O	816	819	All
O	820	821	P
O	822	828	values
O	829	832	are
O	833	836	two
O	836	837	-
O	837	842	sided
O	842	843	.

O	844	846	Of
B-total-participants	847	851	4817
O	852	860	eligible
O	861	869	patients
O	869	870	,
B-intervention-participants	871	874	405
O	875	876	(
O	876	877	8
O	877	878	.
O	878	879	4
O	879	880	%
O	880	881	)
O	882	886	were
B-ethinicity	887	892	black
O	892	893	.

O	894	902	Compared
O	903	907	with
B-control	908	916	nonblack
O	917	925	patients
O	925	926	,
B-intervention	927	932	black
O	933	941	patients
O	942	945	had
O	946	947	a
O	948	954	higher
B-outcome	955	959	rate
I-outcome	960	962	of
I-outcome	963	969	triple
I-outcome	969	970	-
I-outcome	970	978	negative
I-outcome	979	986	disease
O	987	988	(
B-iv-bin-percent	988	990	31
I-iv-bin-percent	990	991	.
I-iv-bin-percent	991	992	9
I-iv-bin-percent	992	993	%
O	994	996	vs
B-cv-bin-percent	997	999	17
I-cv-bin-percent	999	1000	.
I-cv-bin-percent	1000	1001	2
I-cv-bin-percent	1001	1002	%
O	1002	1003	;
O	1004	1005	P
O	1006	1007	<
O	1008	1009	.
O	1009	1012	001
O	1012	1013	)
O	1014	1017	and
O	1018	1019	a
O	1020	1026	higher
O	1027	1031	body
O	1032	1036	mass
O	1037	1042	index
O	1043	1044	(
O	1044	1050	median
O	1050	1051	:
O	1052	1054	31
O	1054	1055	.
O	1055	1056	7
O	1057	1059	vs
O	1060	1062	27
O	1062	1063	.
O	1063	1064	4
O	1065	1067	kg
O	1067	1068	/
O	1068	1069	m
O	1069	1070	(
O	1070	1071	2
O	1071	1072	)
O	1072	1073	;
O	1074	1075	P
O	1076	1077	<
O	1078	1079	.
O	1079	1082	001
O	1082	1083	)
O	1083	1084	.

O	1085	1090	Black
O	1091	1095	race
O	1096	1099	was
O	1100	1113	statistically
O	1114	1127	significantly
O	1128	1138	associated
O	1139	1143	with
O	1144	1149	worse
B-outcome	1150	1157	disease
I-outcome	1157	1158	-
I-outcome	1158	1162	free
I-outcome	1163	1171	survival
O	1172	1173	(
O	1173	1174	5
O	1174	1175	-
O	1175	1179	year
O	1180	1187	disease
O	1187	1188	-
O	1188	1192	free
O	1193	1201	survival
O	1201	1202	,
O	1203	1208	black
O	1209	1211	vs
O	1212	1220	nonblack
O	1220	1221	:
B-iv-bin-percent	1222	1224	76
I-iv-bin-percent	1224	1225	.
I-iv-bin-percent	1225	1226	7
I-iv-bin-percent	1226	1227	%
O	1228	1230	vs
B-cv-bin-percent	1231	1233	84
I-cv-bin-percent	1233	1234	.
I-cv-bin-percent	1234	1235	5
I-cv-bin-percent	1235	1236	%
O	1236	1237	;
O	1238	1244	hazard
O	1245	1250	ratio
O	1251	1253	of
O	1254	1264	recurrence
O	1265	1267	or
O	1268	1273	death
O	1274	1275	=
O	1276	1277	1
O	1277	1278	.
O	1278	1280	58
O	1280	1281	,
O	1282	1284	95
O	1284	1285	%
O	1286	1296	confidence
O	1297	1305	interval
O	1306	1307	=
O	1308	1309	1
O	1309	1310	.
O	1310	1312	19
O	1313	1315	to
O	1316	1317	2
O	1317	1318	.
O	1318	1320	10
O	1320	1321	,
O	1322	1323	P
O	1324	1325	=
O	1326	1327	.
O	1327	1331	0015
O	1331	1332	)
O	1333	1336	and
B-outcome	1337	1344	overall
I-outcome	1345	1353	survival
O	1354	1355	(
B-outcome	1355	1356	5
I-outcome	1356	1357	-
I-outcome	1357	1361	year
I-outcome	1362	1369	overall
I-outcome	1370	1378	survival
O	1378	1379	,
O	1380	1385	black
O	1386	1388	vs
O	1389	1397	nonblack
O	1397	1398	:
B-iv-bin-percent	1399	1401	87
I-iv-bin-percent	1401	1402	.
I-iv-bin-percent	1402	1403	6
I-iv-bin-percent	1403	1404	%
O	1405	1407	vs
B-cv-bin-percent	1408	1410	91
I-cv-bin-percent	1410	1411	.
I-cv-bin-percent	1411	1412	9
I-cv-bin-percent	1412	1413	%
O	1413	1414	;
O	1415	1421	hazard
O	1422	1427	ratio
O	1428	1430	of
O	1431	1436	death
O	1437	1438	=
O	1439	1440	1
O	1440	1441	.
O	1441	1443	49
O	1443	1444	,
O	1445	1447	95
O	1447	1448	%
O	1449	1459	confidence
O	1460	1468	interval
O	1469	1470	=
O	1471	1472	1
O	1472	1473	.
O	1473	1475	05
O	1476	1478	to
O	1479	1480	2
O	1480	1481	.
O	1481	1483	12
O	1483	1484	,
O	1485	1486	P
O	1487	1488	=
O	1489	1490	.
O	1490	1493	025
O	1493	1494	)
O	1495	1497	in
O	1498	1506	patients
O	1507	1511	with
O	1512	1519	hormone
O	1520	1528	receptor
O	1528	1529	-
O	1529	1537	positive
O	1538	1542	HER2
O	1542	1543	-
O	1543	1551	negative
O	1552	1559	disease
O	1560	1563	but
O	1564	1567	not
O	1568	1570	in
O	1571	1579	patients
O	1580	1584	with
O	1585	1591	triple
O	1591	1592	-
O	1592	1600	negative
O	1601	1603	or
O	1604	1608	HER2
O	1608	1609	-
O	1609	1617	positive
O	1618	1625	disease
O	1625	1626	.

O	1627	1629	In
O	1630	1631	a
O	1632	1637	model
O	1638	1642	that
O	1643	1651	included
O	1652	1657	black
O	1658	1662	race
O	1662	1663	,
O	1664	1671	hormone
O	1672	1680	receptor
O	1680	1681	-
O	1681	1689	positive
O	1690	1694	HER2
O	1694	1695	-
O	1695	1703	negative
O	1704	1711	disease
O	1712	1714	vs
O	1715	1720	other
O	1721	1729	subtypes
O	1729	1730	,
O	1731	1734	and
O	1735	1740	their
O	1741	1752	interaction
O	1752	1753	,
O	1754	1757	the
O	1758	1769	interaction
O	1770	1774	term
O	1775	1778	was
O	1779	1792	statistically
O	1793	1804	significant
O	1805	1808	for
O	1809	1816	disease
O	1816	1817	-
O	1817	1821	free
O	1822	1830	survival
O	1831	1832	(
O	1832	1833	P
O	1834	1835	=
O	1836	1837	.
O	1837	1840	027
O	1840	1841	)
O	1842	1845	but
O	1846	1849	not
O	1850	1853	for
O	1854	1861	overall
O	1862	1870	survival
O	1871	1872	(
O	1872	1873	P
O	1874	1875	=
O	1876	1877	.
O	1877	1880	086
O	1880	1881	)
O	1881	1882	.

O	1883	1890	Factors
O	1891	1896	other
O	1897	1901	than
O	1902	1913	disparities
O	1914	1916	in
O	1917	1921	care
O	1922	1924	or
O	1925	1935	aggressive
O	1936	1943	disease
O	1944	1954	contribute
O	1955	1957	to
O	1958	1967	increased
O	1968	1978	recurrence
O	1979	1981	in
O	1982	1987	black
O	1988	1993	women
O	1994	1998	with
O	1999	2006	hormone
O	2007	2015	receptor
O	2015	2016	-
O	2016	2024	positive
O	2025	2031	breast
O	2032	2038	cancer
O	2038	2039	.
